NVO - looking for move upMy MVP system
M: rsi bottoming, rounded w a higher low
V: solid increase in vol
P: steep downward channel; could have nice pop to the upside; I would like the price better if it were forming a base instead of a steep down path, though price did hit a prior support/resistance zone
*Im wondering if
Key facts today
Novo Nordisk has signed a $2.2 billion deal with Septerna to develop treatments for obesity and type 2 diabetes. Shares rose 1.7% to $66.51, then fell 1.1%.
Novo Nordisk's semaglutide, key in Wegovy and Ozempic, will lose patent protection in India in 2026, spurring local firms to produce generics for the $150 billion weight-loss drug market.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.38 USD
14.65 B USD
42.12 B USD
3.36 B
About NOVO NORDISK B A/S
Sector
Industry
CEO
Lars Fruergaard Jørgensen
Website
Headquarters
Bagsværd
Founded
1931
FIGI
BBG000BQBKR3
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Novo Nordisk Stock Chart Fibonacci Analysis 050925Trading Idea
1) Find a FIBO slingshot
2) Check FIBO 61.80% level
3) Entry Point > 411/61.80%
Chart time frame: D
A) 15 min(1W-3M)
B) 1 hr(3M-6M)
C) 4 hr(6M-1year)
D) 1 day(1-3years)
Stock progress: A
A) Keep rising over 61.80% resistance
B) 61.80% resistance
C) 61.80% support
D) Hit the bottom
Novo Nordisk (NVO) – Oversold Reversal + Earnings CatalystNovo Nordisk (NVO) has declined 61.13% from its all-time high of $148 (June 2024), finding support at $57.55. Over the past two weeks, the stock has rebounded over 15%, currently trading around $66.30, with strong reversal signals just ahead of earnings.
This setup presents a compelling opportunity
NVO Thesis earningsEarnings from LLY proved to be good on their fat drugs with concerns on tariffs for other items in their portfolio. Knowing that NVO is primary obesity with deals on the table from CVS and HIMS it is in the line of thinking that earnings will be in line with positive guidance in anticipation of mar
NOV - CONTINUATION OF A DOWNTREND OR START OF A NEWGood Morning,
Hope all is well. NVO has been in a down trend since Feb 26 2025, like most stocks. NVO tried to move past the 70$ price point however it was rejected and is now seeking lower support. Currently for trend there is an ascending channel. A break above the mid-line is bullish, a failure
NVO Novo Nordisk: $195 | The Cure since forever it addresses on major conditions of humans
Diabetes Cardio Alzheimer's
from acquisition to partnering and continuous r&d
this issue is a model to new science and tech companies making it to the next 50 years
key is innovation
opportunity is wait for major crash to upsize for OG investors
or s
Novo Nordisk's The recent drop in Novo Nordisk's stock price is attributed to several factors. A key issue is the company’s struggle to meet the surging demand for its weight-loss drugs, such as Wegovy. Although demand remains strong, investors are concerned about Novo Nordisk's ability to scale up production and
NVO absolutely sweet levelThis downturn is attributed to disappointing clinical trial results for some of its drugs and concerns over potential tariffs affecting Denmark. Additionally, competition from Eli Lilly's successful weight-loss drug trials has impacted investor confidence.
Despite these challenges, analysts note
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NVO is featured.